牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Vertex Pharmaceuticals Inc.首席執行官兼總裁凱瓦爾拉瑪尼·雷什瑪於2024年2月23日完成了9,386股普通股的出售。該交易以每股431.79美元的價格進行，總價值約爲405萬美元。出售後，Kewalramani直接持有Vertex Pharmicals的136,507股股份。根據交易代碼的描述，此次出售是通過交付或預扣證券來支付行使價或納稅義務的一種手段。
Vertex Pharmaceuticals Inc.首席執行官兼總裁凱瓦爾拉瑪尼·雷什瑪於2024年2月23日完成了9,386股普通股的出售。該交易以每股431.79美元的價格進行，總價值約爲405萬美元。出售後，Kewalramani直接持有Vertex Pharmicals的136,507股股份。根據交易代碼的描述，此次出售是通過交付或預扣證券來支付行使價或納稅義務的一種手段。
有用
沒用